Isradipine for the prevention of cyclosporine-induced hypertension in allogeneic bone marrow transplant recipients

Michael Bursztyn, Orly Zelig, Reuven Or, Arnon Nagler

Research output: Contribution to journalArticlepeer-review

Abstract

Background. Hypertension and nephrotoxicity frequently occur in patients who receive cyclosporine therapy after bone marrow transplantation (BMT). Isradipine, a calcium channel entry blocker, has been used successfully in cyclosporine-induced hypertension. Methods. Thirty leukemic patients who received cyclosporine after BMT were randomized to receive isradipine (0.005 mg/kg) from 72 hr before commencement of cyclosporine therapy until day 100 after BMT or placebo. Results. The placebo and isradipine groups were well matched. No differences were found between the isradipine and placebo groups in the level of blood pressure, renal function, marrow engraftment, or mortality. Hypertension incidence was surprisingly low (30% a week after hospital discharge and 10% by day 100 after BMT), and did not differ between the groups. Conclusions. Isradipine does not harm immunohematopoietic reconstitution after BMT; therefore, it may be used in this setting, although the previously reported incidence of hypertension has been exaggerated.

Original languageEnglish
Pages (from-to)1034-1036
Number of pages3
JournalTransplantation
Volume63
Issue number7
DOIs
StatePublished - 15 Apr 1997
Externally publishedYes

Fingerprint

Dive into the research topics of 'Isradipine for the prevention of cyclosporine-induced hypertension in allogeneic bone marrow transplant recipients'. Together they form a unique fingerprint.

Cite this